AQST ▲ +1.4% - Aquestive Therapeutics, Inc. $AQST - Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film Aquestive Therapeutics shares rose 1.4% after the company announced it resubmitted its New Drug Application to the FDA for Anaphylm, a sublingual film formulation of dibutepinephrine for anaphylaxis treatment. The resubmission suggests the company has addressed previous FDA deficiencies, moving the candidate closer to potential approval. 17-SEP-2026 07:00 AM ET